Sensitizing for cis-diamminedichloroplatinum(II) action by hyperthermia in resistant cells

Area of Science:

• Oncology
• Cancer Biology
• Biochemistry

Background:

• Cisplatin resistance in cancer is a major clinical challenge.
• Glutathione levels and heat sensitivity influence chemotherapy response.
• Hyperthermia as an adjunct to chemotherapy is being investigated.

Purpose of the Study:

• To investigate the chemosensitization of cisplatin-resistant Ehrlich ascites tumor (EAT) cells by hyperthermia.
• To evaluate the role of glutathione in cisplatin resistance and heat sensitization.
• To determine the efficacy of combined heat and cisplatin treatment in resistant cancer cells.

Main Methods:

• Comparison of cisplatin-resistant (ER) and non-resistant (EN) EAT cells.
• Assessment of cellular glutathione content.
• Evaluation of heat sensitivity and cisplatin sensitivity.
• Analysis of synergistic effects of combined hyperthermia and cisplatin treatment.

Main Results:

• ER cells exhibited elevated glutathione levels compared to EN cells.
• Depletion of glutathione using BSO did not sensitize ER cells to cisplatin.
• ER cells were less sensitive to heat than EN cells.
• Significant thermal enhancement ratio (TER) for cisplatin toxicity was observed in ER cells at 43°C.
• Combined treatment killed fewer ER cells than EN cells, despite chemosensitization.

Conclusions:

• Hyperthermia can chemosensitize cisplatin-resistant cells, but may not completely overcome resistance.
• The effectiveness of hyperthermia depends on the specific cancer cell's heat sensitivity and TER.
• Combined hyperthermia and cisplatin therapy is indicated for resistant cancers showing sensitivity at clinically relevant temperatures.